Simmunome Receives FRV Investment
Exciting news! Simmunome Inc. has secured an investment from Front Row Ventures!
We are thrilled to partner with Front Row Ventures to continue driving innovation in the areas of oncology, neurodegenerative diseases and regenerative medicine. This investment will help us accelerate the development of our groundbreaking technology that leverages multi-omic data and machine learning to improve the understanding and treatment of complex diseases and predict clinical outcomes.
We would like to thank Front Row Ventures for their confidence in our team and vision, and we look forward to working together. Stay tuned for more updates as we continue to make strides in our mission to improve patient outcomes.